drugset / Trial / NCT04609670

Study of Radiolabeled ALXN2050 in Healthy Adult Males

NCT04609670

Phase 1 Completed 9 enrolled Alexion Pharmaceuticals, Inc.
NaSingle-groupOpen-labelBasic science

Summary

This is an open-label study to assess the absorption, metabolism, excretion, and mass balance of a single oral dose of carbon-14 (\[14C\])-ALXN2050 in healthy adult males.

Timeline

Start
2021-04-12
Primary completion
2021-08-23
Completion
2021-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Vemircopan Small molecule 200 mg Oral

Indications

No indication recorded.